Repros Therapeutics Inc.(R) Reports First Quarter 2015

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Repros Therapeutics Inc.(R) Reports First Quarter 2015 Financial Results

THE WOODLANDS, Texas, May 7, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq: RPRX ) today announced financial results for the first quarter ended March 31, 2015.

Financial Results

Net loss for the three month period ended March 31, 2015, was ($8.5) million, or ($0.35) per share, as compared to a net loss of ($8.8) million, or ($0.38) per share, for the same period in 2014. The decrease in net loss for the three month period ended March 31, 2015 as compared to the same period in 2014 was primarily due to decreased clinical development expenses related to the Company's enclomiphene product candidate, formerly known as Androxal®, partially offset by increases in clinical development expenses related to Proellex®, research and development payroll and benefits expenses and increased legal expenses.

While preparing its financial statements for the year ended December 31, 2014, the Company identified a prior period error related to its accounting for patent costs. The Company concluded this error was not material individually or in the aggregate to any of the prior reporting periods, and therefore, no restatements of previously issued financial statements were necessary. As such, revisions for the quarter ended March 31, 2014 are reflected in the financial statements herein. The quarter ended March 31, 2015 was not affected.         

Research and development ("R&D") expenses decreased 3%, or approximately $248,000, to $7.3 million for the three month period ended March 31, 2015, as compared to $7.6 million for the same period in the prior year. R&D expenses related to the clinical development of enclomiphene decreased 19%, or approximately $929,000, for the three month period ended March 31, 2015 as compared to the prior year period, primarily due to the completion of all Phase 3 clinical trials, partially offset by the payment of $2.3 million to the FDA associated with the submission of our NDA for the product candidate. R&D expenses related to the clinical development of Proellex® increased 72%, or approximately $343,000, from the 2014 period to the 2015 period, due to increased expenses associated with our Phase 2B clinical trials for the treatment of uterine fibroids. Payroll and benefits expenses increased 21%, or approximately $227,000, to $1.3 million for the three month period ended March 31, 2015 as compared to $1.1 million for the same period in the prior year. Included in payroll and benefits expense is a charge for non-cash stock-based compensation of $574,000 for the three month period ended March 31, 2015 as compared to $479,000 for the same period in the prior year. Additionally, salaries for the three month period ended March 31, 2015 were $579,000 as compared to $480,000 for the same period in the prior year. Operating and occupancy expenses increased 11%, or approximately $111,000, to $1.1 million for the three month period ended March 31, 2015 as compared to $1.0 million for the same period in the prior year, primarily due to increased legal expenses.

General and administrative ("G&A") expenses decreased 2%, or approximately $21,000, to $1.2 million for the three month period ended March 31, 2015 as compared to $1.2 million for the same period in the prior year. Payroll and benefits expense increased 1%, or approximately $7,000, to $743,000 for the three month period ended March 31, 2015 as compared to $736,000 for the same period in the prior year. Included in payroll and benefits expense is a charge for non-cash stock based compensation expense of $448,000 for the three month period ended March 31, 2015 as compared to $441,000 for the same period in the prior year. Additionally, salaries for the three month period ended March 31, 2015 were $255,000 as compared to $247,000 for the same period in the prior year.  G&A operating and occupancy expense decreased 6%, or approximately $28,000, to $462,000 for the three month period ended March 31, 2015 as compared to $490,000 for the same period in the prior year primarily due to a decrease in legal expenses.

Interest income decreased to $1,000 for the three month period ended March 31, 2015 as compared to $2,000 for the same period in the prior year. The decrease for the three month period ended March 31, 2015 as compared to the same period in the prior year was primarily due to decreased cash balances.

Liquidity and Capital Resources

The Company had cash and cash equivalents of $37.9 million as of March 31, 2015 as compared to $46.6 million as of December 31, 2014. Net cash of approximately $8.8 million and $7.9 million was used in operating activities during the three month periods ended March 31, 2015 and 2014, respectively. The major use of cash for operating activities for the three month period ended March 31, 2015 was to fund our clinical development programs, including $2.3 million payment to the FDA associated with the submission of our NDA for our enclomiphene product candidate, and associated administrative costs. No cash was used in investing activities during the three month period ended March 31, 2015. Cash provided by financing activities during the three month period ended March 31, 2015 was approximately $102,000 due to the receipt of that amount from a former 10% shareholder of the Company in accordance with Section 16(a) under the Securities Exchange Act of 1934, as amended.

As of March 31, 2015, the Company had 24,276,173 shares of common stock outstanding.

About Repros Therapeutics Inc. ®

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties and other factors that could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," "plan," "seek," "could," "can," "should" or similar expressions. These statements are based on assumptions that the Company has made in light of the Company's experience in the industry, as well as the Company's perceptions of historical trends, current conditions, expected future developments and other factors the Company believes are appropriate in these circumstances. Any such statements are based on current expectations that involve a number of known and unknown risks, uncertainties and other factors that may cause actual events to be materially different from those expressed or implied by such forward-looking statements, including the potential approval of our NDA for our enclomiphene product candidate, the ability to have success in the clinical development of the Company's technologies, the reliability of interim results to predict final study outcomes, the ability to protect the Company's intellectual property rights and such other risks as are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov . Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at http://www.reprosrx.com .

REPROS THERAPEUTICS INC. AND SUBSIDIARY
     
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited and in thousands except per share amounts)
   
  Three Months Ended March 31,
  2015 2014
     
     
Revenues and other income  $ 1  $ 2
     
Expenses    
Research and development  7,321  7,569
General and administrative  1,205  1,226
Total expenses  8,526  8,795
     
Net loss  $ (8,525)  $ (8,793)
     
Net loss per share - basic and diluted  $ (0.35)  $ (0.38)
     
Weighted average shares used in loss per share calculation:    
Basic  24,276  23,033
Diluted  24,276  23,033
     
CONSOLIDATED BALANCE SHEETS
(unaudited and in thousands)
     
  March 31, 2015 December 31, 2014
     
     
Cash and cash equivalents  $ 37,875  $ 46,620
Prepaid expenses and other currents assets  569  289
Fixed assets (net)  22  32
Total assets  $ 38,466  $ 46,941
     
Accounts payable and accrued expenses   $ 1,952  $ 2,924
Stockholders' equity  36,514  44,017
     
Total liabilities and stockholders' equity  $ 38,466  $ 46,941

Investor Relations: Thomas Hoffmann The Trout Group (646) 378-2931

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 139

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 184

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 207

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 146

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 168

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 108

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 79

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading

Top 5 Most Recently Viewed Articles

James Lukezic's Triumph: FINRA Case Dismissed, Reputation Restored

Updated Category News Views 278

James Lukezic's Journey to Exoneration NEW YORK – After undergoing extensive hearings, James Lukezic, the Managing Principal of Old Slip Capital Management, has successfully cleared his name of unfounded allegations in a substantial FINRA case. This decision represents a significant milestone for Lukezic, who faced serious accusations surrounding five trades that...

Continue Reading
DraftKings Inc. Reports Impressive Q2 Growth and Strong Future Prospects

Updated Category News Views 175

DraftKings Inc. Achieves Record Revenue in Q2 DraftKings Inc. announced remarkable financial results for the second quarter, showcasing a significant leap in its performance. This includes a record revenue of $1.51 billion, representing a 37% increase year-over-year. This impressive growth surpassed analyst expectations, as the consensus estimate was only $1.39 billion....

Continue Reading
Trellis Bioscience's $9M Shot at Revolutionizing PJI Treatment

Updated Category News Views 40

New Hope on the Horizon for Joint Implant Infections When you hear about prosthetic joint infections (PJIs), 'devastating' doesn’t quite cover it. We’re talking something that’s hard to tackle, ends up costlier than a Beverly Hills tax bill, and drains quality of life like nothing else. Now, Trellis Bioscience seems to think there's hope on the way. The company just...

Continue Reading
Dionisio Gutiérrez Honored with Prestigious Award by Spain's King

Updated Category News Views 196

Dionisio Gutiérrez's Recognition and Achievements Dionisio Gutiérrez, a prominent figure known for his contributions to civic and business advancements, has recently been honored with the XI Enrique V. Iglesias Award. This prestigious accolade, presented by King Felipe VI of Spain, acknowledges Gutiérrez's significant impact within the Ibero-American space,...

Continue Reading
Vivani Medical Advances in Clinical Trials for GLP-1 Implant

Updated Category News Views 238

Vivani Medical, Inc. (NASDAQ: VANI) recently received approval from the Bellberry Human Research Ethics Committee and an acknowledgment from Australia’s Therapeutic Goods Administration for its first-in-human clinical trial. This significant step centers around the company's innovative GLP-1 (exenatide) implant targeting overweight and obese individuals, marking a...

Continue Reading